Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1990 Feb;53(2):93–95. doi: 10.1136/jnnp.53.2.93

The modern management of Parkinson's disease.

N Quinn 1
PMCID: PMC487942  PMID: 2107279

Full text

PDF
93

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birkmayer W., Knoll J., Riederer P., Youdim M. B., Hars V., Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm. 1985;64(2):113–127. doi: 10.1007/BF01245973. [DOI] [PubMed] [Google Scholar]
  2. Birkmayer W., Riederer P., Youdim M. B., Linauer W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm. 1975;36(3-4):303–326. doi: 10.1007/BF01253131. [DOI] [PubMed] [Google Scholar]
  3. Chaudhuri K. R., Critchley P., Abbott R. J., Pye I. F., Millac P. A. Subcutaneous apomorphine for on-off oscillations in Parkinson's disease. Lancet. 1988 Nov 26;2(8622):1260–1260. doi: 10.1016/s0140-6736(88)90860-4. [DOI] [PubMed] [Google Scholar]
  4. Cohen G., Spina M. B. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol. 1989 Nov;26(5):689–690. doi: 10.1002/ana.410260518. [DOI] [PubMed] [Google Scholar]
  5. Cooper D. R., Marrel C., Testa B., van de Waterbeemd H., Quinn N., Jenner P., Marsden C. D. L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clin Neuropharmacol. 1984;7(1):89–98. doi: 10.1097/00002826-198403000-00005. [DOI] [PubMed] [Google Scholar]
  6. Corsini G. U., Del Zompo M., Gessa G. L., Mangoni A. Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease. Lancet. 1979 May 5;1(8123):954–956. doi: 10.1016/s0140-6736(79)91725-2. [DOI] [PubMed] [Google Scholar]
  7. Csanda E., Tárczy M. Selegiline in the early and late phases of Parkinson's disease. J Neural Transm Suppl. 1987;25:105–113. [PubMed] [Google Scholar]
  8. Dexter D. T., Wells F. R., Lees A. J., Agid F., Agid Y., Jenner P., Marsden C. D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem. 1989 Jun;52(6):1830–1836. doi: 10.1111/j.1471-4159.1989.tb07264.x. [DOI] [PubMed] [Google Scholar]
  9. Dexter D., Carter C., Agid F., Agid Y., Lees A. J., Jenner P., Marsden C. D. Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet. 1986 Sep 13;2(8507):639–640. doi: 10.1016/s0140-6736(86)92471-2. [DOI] [PubMed] [Google Scholar]
  10. Frankel J. P., Lees A. J., Kempster P. A., Stern G. M. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990 Feb;53(2):96–101. doi: 10.1136/jnnp.53.2.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Goetz C. G., Olanow C. W., Koller W. C., Penn R. D., Cahill D., Morantz R., Stebbins G., Tanner C. M., Klawans H. L., Shannon K. M. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. N Engl J Med. 1989 Feb 9;320(6):337–341. doi: 10.1056/NEJM198902093200601. [DOI] [PubMed] [Google Scholar]
  12. Hardie R. J., Lees A. J., Stern G. M. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain. 1984 Jun;107(Pt 2):487–506. doi: 10.1093/brain/107.2.487. [DOI] [PubMed] [Google Scholar]
  13. Heikkila R. E., Manzino L., Cabbat F. S., Duvoisin R. C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature. 1984 Oct 4;311(5985):467–469. doi: 10.1038/311467a0. [DOI] [PubMed] [Google Scholar]
  14. Knoll J. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron. J Neural Transm Suppl. 1987;25:45–66. [PubMed] [Google Scholar]
  15. Poewe W., Kleedorfer B., Gerstenbrand F., Oertel W. Subcutaneous apomorphine in Parkinson's disease. Lancet. 1988 Apr 23;1(8591):943–943. doi: 10.1016/s0140-6736(88)91755-2. [DOI] [PubMed] [Google Scholar]
  16. Pollak P., Champay A. S., Hommel M., Perret J. E., Benabid A. L. Subcutaneous apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989 Apr;52(4):544–544. doi: 10.1136/jnnp.52.4.544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rinne U. K. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology. 1987 May;37(5):826–828. doi: 10.1212/wnl.37.5.826. [DOI] [PubMed] [Google Scholar]
  18. Rinne U. K. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology. 1989 Mar;39(3):336–339. doi: 10.1212/wnl.39.3.336. [DOI] [PubMed] [Google Scholar]
  19. Rossetti Z. L., Sotgiu A., Sharp D. E., Hadjiconstantinou M., Neff N. H. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and free radicals in vitro. Biochem Pharmacol. 1988 Dec 1;37(23):4573–4574. doi: 10.1016/0006-2952(88)90674-0. [DOI] [PubMed] [Google Scholar]
  20. Ruggieri S., Stocchi F., Carta A., Agnoli A. Side-effects of subcutaneous apomorphine in Parkinson's disease. Lancet. 1989 Mar 11;1(8637):566–566. doi: 10.1016/s0140-6736(89)90116-5. [DOI] [PubMed] [Google Scholar]
  21. SCHWAB R. S., AMADOR L. V., LETTVIN J. Y. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc. 1951;56:251–253. [PubMed] [Google Scholar]
  22. Schapira A. H., Cooper J. M., Dexter D., Jenner P., Clark J. B., Marsden C. D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1989 Jun 3;1(8649):1269–1269. doi: 10.1016/s0140-6736(89)92366-0. [DOI] [PubMed] [Google Scholar]
  23. Singer T. P., Castagnoli N., Jr, Ramsay R. R., Trevor A. J. Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem. 1987 Jul;49(1):1–8. doi: 10.1111/j.1471-4159.1987.tb03384.x. [DOI] [PubMed] [Google Scholar]
  24. Stibe C. M., Lees A. J., Kempster P. A., Stern G. M. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988 Feb 20;1(8582):403–406. doi: 10.1016/s0140-6736(88)91193-2. [DOI] [PubMed] [Google Scholar]
  25. Tetrud J. W., Langston J. W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 1989 Aug 4;245(4917):519–522. doi: 10.1126/science.2502843. [DOI] [PubMed] [Google Scholar]
  26. Youdim M. B., Collins G. G., Sandler M., Bevan Jones A. B., Pare C. M., Nicholson W. J. Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature. 1972 Mar 31;236(5344):225–228. doi: 10.1038/236225b0. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES